The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether–lumefantrine (AL)

High therapeutic efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Somalia

July 12, 2019 - 16:32 -- Open Access
Author(s): 
Marian Warsame, Abdillahi Mohamed Hassan, Pascal Ringwald, et al.
Reference: 
Malaria Journal 2019 18:231, 11 July 2019

Artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DHA/PPQ) are the recommended first- and second-line treatments, respectively, for uncomplicated falciparum malaria in Somalia. The studies reported here were conducted to assess the efficacy of these artemisinin-based combinations and the mutations in Plasmodium falciparum K13-propeller (Pfk13) domain and amplification in Pfplasmepsin 2 (Pfpm2) gene in Somalia.

Country: 
Medical Treatment: 

Efficacy and safety of artemether–lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial

May 28, 2019 - 11:31 -- Open Access
Author(s): 
Clifford G. Banda, Mike Chaponda, Victor Mwapasa, et al.
Reference: 
Malaria Journal 2019 18:180, 24 May 2019

HIV-infected individuals on antiretroviral therapy (ART) require treatment with artemisinin-based combination therapy (ACT) when infected with malaria. Artemether–lumefantrine (AL) is the most commonly used ACT for treatment of falciparum malaria in Africa but there is limited evidence on the safety and efficacy of AL in HIV-infected individuals on ART, among whom drug–drug interactions are expected. Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events was assessed in HIV-infected individuals on efavirenz-based ART with uncomplicated falciparum malaria treated with AL.

Country: 
Medical Treatment: 

Malaria case management commodity supply and use by community health workers in Mozambique, 2017

February 26, 2019 - 15:18 -- Open Access
Author(s): 
Elizabeth Davlantes, Cristolde Salomao, Flavio Wate, Deonilde Sarmento, Humberto Rodrigues, Eric S. Halsey, Lauren Lewis, Baltazar Candrinho and Rose Zulliger
Reference: 
Malaria Journal 2019 18:47, 21 February 2019

Variations in geographic and seasonal malaria commodity needs should be considered in CHW kit distribution planning in Mozambique.

Country: 
Medical Treatment: 

Prescriber practices and patient adherence to artemisinin-based combination therapy for the treatment of uncomplicated malaria in Guinea, 2016

January 30, 2019 - 16:02 -- Open Access
Author(s): 
Alioune Camara, Leah F. Moriarty, Mateusz Plucinski, et al.
Reference: 
Malaria Journal 2019 18:23, 25 January 2019

Although there were more reported adverse events associated with ASAQ when compared with AL, both prescribers and patients were found to be mostly adherent to ACT for the treatment of malaria, regardless of ACT type.

Country: 
Medical Treatment: 

Efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated malaria in Papua New Guinea

October 16, 2018 - 14:20 -- Open Access
Tags: 
Author(s): 
Livingstone Tavul, Manuel W. Hetzel, Ivo Mueller, et al.
Reference: 
Malaria Journal 2018 17:350, 5 October 2018

AL and DHA-PPQ were efficacious as first- and second-line treatments for uncomplicated malaria in PNG.

Medical Treatment: 

A randomized trial of dihydroartemisinin–piperaquine versus artemether–lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali

October 16, 2018 - 14:15 -- Open Access
Author(s): 
Souleymane Dama, Hamidou Niangaly, Ogobara K. Doumbo, et al.
Reference: 
Malaria Journal 2018 17:347, 5 October 2018

A total of 317 uncomplicated malaria patients were enrolled, with 159 in DHA–PQ arm and 158 in AL arm.

Country: 
Medical Treatment: 

Effectiveness and safety of 3 and 5 day courses of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar

July 15, 2018 - 16:52 -- Open Access
Author(s): 
Kyaw Myo Tun, Atthanee Jeeyapant, Frank Smithuis, et al.
Reference: 
Malaria Journal 2018 17:258, 11 July 2018

Despite a high prevalence of k13 mutations, the current first-line treatment, AL, was still highly effective in this area of South-East Myanmar.

Medical Treatment: 

Intermittent screening and treatment with artemether–lumefantrine versus intermittent preventive treatment with sulfadoxine–pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria

July 6, 2018 - 16:52 -- Open Access
Tags: 
Author(s): 
Ekpereonne Esu, Nicole Berens-Riha, Michael Pritsch, Nuria Nwachuku, Thomas Loescher and Martin Meremikwu
Reference: 
Malaria Journal 2018 17:251, 6 July 2018

The trial results suggest that in an area of high malaria transmission with moderate sulfadoxine–pyrimethamine resistance, ISTp with artemether–lumefantrine may be an effective strategy for controlling malaria in pregnancy.

Medical Treatment: 

Adherence to treatment with artemether–lumefantrine or amodiaquine–artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial

June 5, 2018 - 14:44 -- Open Access
Author(s): 
Kristin Banek, Emily L. Webb, Samuel Juana Smith, Daniel Chandramohan and Sarah G. Staedke
Reference: 
Malaria Journal 2018 17:222, 4 June 2018

Self-reported adherence was high for both AL and AQAS, but varied by site.

Person: 
Country: 
Medical Treatment: 

Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment

June 5, 2018 - 14:42 -- Open Access
Author(s): 
Johanna M. Roth, Patrick Sawa, George Omweri, Victor Osoti, Nicodemus Makio, John Bradley, Teun Bousema, Henk D. F. H. Schallig and Pètra F. Mens
Reference: 
Malaria Journal 2018 17:223, 4 June 2018

This study indicates that female gametocyte clearance may be slightly faster after AL compared to PA.

Medical Treatment: 

Pages

Subscribe to RSS - artemether–lumefantrine (AL)